前列腺癌神经内分泌分化的分子成像：病例系列 - Suppr

Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.

作者信息

Iravani Amir, Mitchell Catherine, Akhurst Tim, Sandhu Shahneen, Hofman Michael S, Hicks Rodney J

机构信息

Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

出版信息

Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205. doi: 10.1016/j.clgc.2021.01.008. Epub 2021 Feb 9.

DOI:10.1016/j.clgc.2021.01.008

PMID:33678552

Abstract

摘要

相似文献

Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.前列腺癌神经内分泌分化的分子成像：病例系列

Clin Genitourin Cancer. 2021 Aug;19(4):e200-e205. doi: 10.1016/j.clgc.2021.01.008. Epub 2021 Feb 9.

Somatostatin imaging of neuroendocrine-differentiated prostate cancer.神经内分泌分化型前列腺癌的生长抑素成像。

Clin Nucl Med. 2015 Jun;40(6):540-1. doi: 10.1097/RLU.0000000000000776.

Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.用于神经内分泌分化型前列腺癌诊断与治疗的放射性药物

Curr Radiopharm. 2017;10(1):6-15. doi: 10.2174/1874471009666161229123126.

68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation.68Ga-DOTATOC 和 68Ga-PSMA PET/CT 揭示了一例前列腺癌伴神经内分泌分化。

Clin Nucl Med. 2016 Dec;41(12):959-960. doi: 10.1097/RLU.0000000000001419.

Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.前列腺腺癌伴神经内分泌分化：18F-FDG PET/CT 和 68Ga-DOTANOC PET/CT 相对于 68Ga-PSMA PET/CT 的潜在效用。

Clin Nucl Med. 2018 Apr;43(4):248-249. doi: 10.1097/RLU.0000000000002013.

Tumor imaging and therapy using radiolabeled somatostatin analogues.使用放射性标记的生长抑素类似物进行肿瘤成像和治疗。

Acc Chem Res. 2009 Jul 21;42(7):873-80. doi: 10.1021/ar800188e.

18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.18F-FDG、68Ga-DOTATATE 和 68Ga-PSMA 阳性转移性大细胞神经内分泌前列腺肿瘤。

Clin Nucl Med. 2019 Jan;44(1):53-54. doi: 10.1097/RLU.0000000000002322.

Molecular Imaging in Neuroendocrine Differentiation of Prostate Cancer: 68Ga-PSMA Versus 68Ga-DOTA NOC PET-CT.前列腺癌神经内分泌分化的分子影像学：68Ga-PSMA 与 68Ga-DOTA-NOC PET-CT 比较。

Clin Nucl Med. 2017 May;42(5):410-413. doi: 10.1097/RLU.0000000000001618.

Somatostatin receptor imaging.生长抑素受体显像

Semin Nucl Med. 2002 Apr;32(2):84-91. doi: 10.1053/snuc.2002.31022.

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).用铟-111 喷曲肽（奥曲肽扫描）对神经内分泌肿瘤进行生长抑素受体显像。

Semin Nucl Med. 1995 Jul;25(3):251-61. doi: 10.1016/s0001-2998(95)80014-x.

引用本文的文献

Impact of Metastatic Microenvironment on Physiology and Metabolism of Small Cell Neuroendocrine Prostate Cancer Patient-Derived Xenografts.转移微环境对小细胞神经内分泌前列腺癌患者来源异种移植瘤生理和代谢的影响

Cancers (Basel). 2025 Jul 18;17(14):2385. doi: 10.3390/cancers17142385.

Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.镥-177-PSMA-617或卡巴他赛治疗转移性前列腺癌：随机2期TheraP试验的循环肿瘤DNA分析

Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03704-9.

Prognostic value of [F]FDG- and PSMA-PET in patients evaluated for [Lu]Lu-PSMA therapy of mCRPC.[F]FDG和PSMA-PET在接受[Lu]Lu-PSMA治疗评估的mCRPC患者中的预后价值。

Eur J Nucl Med Mol Imaging. 2025 Mar 21. doi: 10.1007/s00259-025-07198-y.

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received Lu-PSMA-617: Importance of F-FDG-Avid Discordant Findings.基于正电子发射断层扫描（PET）的转移性去势抵抗性前列腺癌符合VISION标准且接受Lu-PSMA-617治疗的患者的治疗资格及结局：氟代脱氧葡萄糖（F-FDG）摄取不一致发现的重要性

J Nucl Med. 2025 Jan 3;66(1):47-53. doi: 10.2967/jnumed.124.268167.

Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.三探针 PET 成像在 mCRPC 患者中确定的瘤内转移灶异质性及其与生存的相关性：3TMPO 队列研究。

J Nucl Med. 2024 Nov 1;65(11):1710-1717. doi: 10.2967/jnumed.124.268020.

PET/CT and Conventional Imaging for the Assessment of Neuroendocrine Prostate Cancer: A Systematic Review.用于评估神经内分泌前列腺癌的PET/CT与传统成像：一项系统评价

Cancers (Basel). 2023 Sep 3;15(17):4404. doi: 10.3390/cancers15174404.

Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.转移性去势抵抗性前列腺癌伴治疗诱导神经内分泌分化的多靶点分子成像

Diagnostics (Basel). 2022 Jun 3;12(6):1387. doi: 10.3390/diagnostics12061387.

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms.分子影像学表型用于选择和监测神经内分泌肿瘤的放射性配体治疗。

Cancer Imaging. 2022 Jun 3;22(1):25. doi: 10.1186/s40644-022-00465-3.

Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.鉴定与前列腺癌细胞中 PSMA 示踪剂摄取相关的谷氨酸-脲基-赖氨酸的替代蛋白靶标。

Proc Natl Acad Sci U S A. 2022 Jan 25;119(4). doi: 10.1073/pnas.2025710119.

Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.SV2A 靶向 PET 成像用于前列腺癌神经内分泌分化的无创评估的验证。

Int J Mol Sci. 2021 Dec 3;22(23):13085. doi: 10.3390/ijms222313085.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献